Deferoxamine therapy for intracerebral hemorrhage: A systematic review
#MMPMID29566000
Zeng L
; Tan L
; Li H
; Zhang Q
; Li Y
; Guo J
PLoS One
2018[]; 13
(3
): e0193615
PMID29566000
show ga
Intracerebral hemorrhage (ICH) is a significant cause of morbidity and mortality
worldwide. Several recent controlled trials have reported that deferoxamine (DFX)
therapy appears to be effective for ICH. The aim of this study was to perform a
systematic review of DFX therapy for ICH patients and evaluate the efficacy and
safety of DFX therapy for ICH patients. We searched Medline, Embase, the Cochrane
Database of Systematic Reviews, clinicaltrials.gov, all Chinese databases and the
reference lists of all included studies and review articles. We then performed a
systematic review of studies involving the administration of DFX following ICH.
Only two studies were included, a prospective, randomized clinical trial and a
prospective,observational cohort study with concurrent groups. Qualitative
analysis of each study revealed one randomized controlled trial of moderate
quality with a moderate risk of bias and one observational cohort study of
moderate quality with a moderate risk of bias. DFX may be an effective treatment
for edema in patients with ICH. However, due to the small number of trials and
small sample sizes of these trials, insufficient evidence exists to determine the
effect of DFX on neurologic outcomes after ICH and the safety of this
intervention. Further investigation is required before DFX can become a routine
treatment for ICH.
|Cerebral Hemorrhage/*drug therapy
[MESH]
|Deferoxamine/adverse effects/pharmacology/*therapeutic use
[MESH]
free
free
free
